EGFR is an important therapeutic target for therapy with anti-EGFR antibodies, however, interestingly, the expression of EGFR is not used for patient selection due to reports of response to cetuximab in mCRC patients with EGFR negative tumours [14]. The gene discussed is EGFR; the disease is neoplasm.